PT-141 (Bremelanotide): Sourcing, Documentation and Price

PT-141 is the research code for bremelanotide, a synthetic cyclic heptapeptide and melanocortin receptor agonist. It is also referred to by the synonym bremelanotide acetate in some catalogue listings. The compound is a cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a melanocortin receptor agonist. Identifiers: the free base has the molecular formula C50H68N14O10 and a molecular weight of approximately 1025.2 g/mol. The sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The pathway the research centres on is the melanocortin receptor family, with activity characterised at MC1R, MC3R, MC4R and MC5R in published receptor-binding work.

PT-141 (Bremelanotide) is supplied as a lyophilised powder for laboratory research use only. It is not a therapeutic product, and no human dose is provided here. The clinical documentation summarised below describes trials in premenopausal women with hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD); those studies were conducted under investigator and regulatory oversight and are cited for reference only.

Research Studies

Bremelanotide and melanocortin receptor binding at MC4R

Bremelanotide is a cyclic heptapeptide analog of alpha-MSH. Its research interest centres on the melanocortin receptor family, particularly MC4R, which is expressed in the central nervous system. In vitro receptor-binding studies have characterised bremelanotide as a non-selective melanocortin receptor agonist with affinity at MC1R, MC3R, MC4R and MC5R. The MC4R subtype has been the focus of much of the mechanistic work because of its role in central signalling pathways. These findings are from in vitro and animal models; they do not establish effects in humans.

Bremelanotide and premenopausal women with HSDD (Phase 3, NCT02338960)

A Phase 3, randomised, double-blind, placebo-controlled, parallel-group trial with an optional open-label extension evaluated the efficacy of bremelanotide administered subcutaneously on an as-needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females [1]. The study design specified subcutaneous administration and an as-needed dosing schedule. The population was premenopausal females with a diagnosis of HSDD. This citation describes the trial design and population; it does not report outcome values here.

Bremelanotide and premenopausal women with HSDD (Phase 3, NCT02333071)

A second Phase 3, randomised, double-blind, placebo-controlled, parallel-group trial with an optional open-label extension evaluated the efficacy of bremelanotide administered subcutaneously on an as-needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females [2]. The design and population were comparable to the companion Phase 3 study. Both trials used subcutaneous administration and an as-needed schedule. No outcome data are reproduced in this summary.

Bremelanotide and premenopausal women with FSAD and/or HSDD (NCT01382719)

A trial was designed to evaluate the efficacy and safety of three fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women [3]. The study specified three fixed dose levels and home-use conditions. The population was premenopausal women with FSAD, HSDD, or mixed FSAD/HSDD. This citation describes the trial design; it does not report outcome values here.

Bremelanotide and women with FSAD (intranasal, NCT00425256)

An 8-week at-home study was designed to explore efficacy endpoints and evaluate the safety of intranasal bremelanotide in women with female sexual arousal disorder [4]. Efficacy was assessed against a parallel placebo group. This study used the intranasal route, in contrast to the subcutaneous route used in the Phase 3 HSDD trials. The population was women with FSAD. No outcome data are reproduced in this summary.

Bremelanotide and route of administration across studies

The clinical documentation cited here spans two routes of administration. The Phase 3 HSDD trials and the fixed-dose FSAD/HSDD trial used subcutaneous administration [1][2][3]. The earlier FSAD study used intranasal administration [4]. The table below compares the routes and populations across the cited studies.

Bremelanotide and dosing schedules in the cited trials

The Phase 3 HSDD trials specified as-needed subcutaneous administration [1][2]. The fixed-dose trial specified as-needed subcutaneous administration under home-use conditions [3]. The intranasal FSAD study was an 8-week at-home study [4]. These descriptions are of trial designs and do not constitute dosing guidance for any human use. No dose, schedule, or administration instruction is provided on this page for human use.

Bremelanotide and the melanocortin pathway in animal and in vitro models

Mechanistic work on bremelanotide has been conducted in in vitro receptor-binding assays and in animal models. These studies characterise the compound as a melanocortin receptor agonist and examine signalling at MC4R and related subtypes. Such findings are animal-only or in vitro and do not establish effects in humans. The clinical trials cited above were conducted in premenopausal women and women with FSAD, and are separate from the preclinical mechanistic literature.

Bremelanotide and documentation for laboratory sourcing

For laboratory sourcing, the documentation typically associated with PT-141 includes a certificate of analysis (CoA), a high-performance liquid chromatography (HPLC) purity report, and a mass spectrometry (MS) identity confirmation. The identifiers listed at the top of this page — molecular formula C50H68N14O10, molecular weight approximately 1025.2 g/mol, and the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — are the values a CoA would be expected to confirm. Researchers should verify that the CoA matches the lot number on the vial and that the purity method is stated. This page does not provide a price, as pricing is subject to catalogue and lot variation; consult the product listing for current availability.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder. https://clinicaltrials.gov/study/NCT02338960
• [2] ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder. https://clinicaltrials.gov/study/NCT02333071
• [3] ClinicalTrials.gov. Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder. https://clinicaltrials.gov/study/NCT01382719
• [4] ClinicalTrials.gov. Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD). https://clinicaltrials.gov/study/NCT00425256